



HTG Molecular Diagnostics Announces the Institute of Oncology Research Has Adopted the HTG EdgeSeq Technology in its Genomics Facility

October 23, 2018

HTG's extraction-free, targeted next-generation sequencing technology adopted to support the IOR's research and clinical trials in hematological cancers and solid tumors

TUCSON, Ariz., Oct. 23, 2018 (GLOBE NEWSWIRE) -- [HTG Molecular Diagnostics](#), Inc. (Nasdaq: HTGM) ("HTG"), a provider of instruments, reagents, and services for molecular profiling applications, today announced that the Institute of Oncology Research ("IOR") is now running the HTG EdgeSeq technology for extraction-free, targeted next-generation sequencing ("NGS") in its genomics facility. The technology will support the IOR's research and clinical trials in hematological cancers and solid tumors.

"We are honored to have this prestigious group select our technology to support its research and clinical trials," said TJ Johnson, Chief Executive Officer of HTG Molecular. "The IOR is a terrific partner and we look forward to helping it discover the next-generation of cancer therapies."

Dr. Francesco Bertoni, IOR Vice Director and VP of the Project Group Lymphoma of the Swiss Group for the Clinical Cancer Research said, "HTG EdgeSeq technology is a great addition and I am pleased to have it in our genomics facility. The technology allows us to look at different aspects of cancer, from the immune-infiltrates to the expression levels of a large panel of genes, and to the activation of specific pathways. It also allows for the possibility to determine the cell of origin of diffuse large B-cell lymphomas from a small tumor section, alongside the levels of important genes such as BCL2 or MYC. The HTG EdgeSeq technology allows us to analyze a broad dynamic range of samples with extremely small sample sizes. This is a tremendous advantage for us, and we look forward to future discoveries."

About IOR

The Institute of Oncology Research, affiliated with the Università Della Svizzera Italiana and with the Oncology Institute of Southern Switzerland, is located in Bellinzona, Canton Ticino, Switzerland. The young investigators focus on hematological cancers and solid tumors, such as prostate cancer, integrating biological, genomics and molecular approaches with preclinical and translational studies to understand disease and identify novel treatment strategies. Thanks to the strong links with local, national and international institutions, IOR investigators can integrate the basic research with the clinical practice.

About HTG

HTG is focused on NGS-based molecular profiling. The proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG's customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries and ultimately to identify treatment options. HTG's mission is to empower precision medicine at the local level.

Safe Harbor Statement:

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the scope of the IOR's future use of HTG's EdgeSeq technology at its genomics facility and the anticipated benefits or outcomes from such use. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management's current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation, the risk that the IOR may choose to use alternative molecular sequencing technology in the future and risks inherent to cancer research and clinical trials. These and other factors are described in greater detail in our filings with the Securities and Exchange Commission, including without limitation our Quarterly Report on Form 10-Q for the quarter ended June 30, 2018. All forward-looking statements contained in this press release speak only as of the date on which they were made, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Contact:

Ashley R. Robinson
LifeSci Advisors, LLC
Phone: (617) 535-7742

Source: HTG Molecular Diagnostics, Inc.



Source: HTG Molecular Diagnostics, Inc.